Artelo Biosciences Will Present at BIO-Europe 2026
The company will detail its ART26.12 inhibitor research in Cologne on November 10, 2026.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do clinical trial updates from pharmaceutical companies increase your trust in future medical treatment options?
Artelo Biosciences has been selected to present its research on ART26.12 at the upcoming BIO-Europe 2026 conference in Cologne, Germany. The company presentation is scheduled to take place on November 10, 2026, at 4:15pm CET.
Why it matters
The appearance marks Artelo Biosciences' first time participating in the conference, where leadership will seek to establish strategic partnerships. The firm intends to leverage the event to advance outreach regarding its pain and inflammation drug development pipeline.
ART26.12 is a designed inhibitor of fatty acid binding protein 5 that showed reduced osteoarthritis-associated pain in animals over a 4-week period. Nonclinical studies indicated the drug caused less stomach tissue damage than naproxen.
The players
Artelo Biosciences
This is a biopharmaceutical company headquartered in Solana Beach, California, that focuses on developing treatments for pain and inflammation.
Andrew Yates
He is the representative for Artelo Biosciences who will present the company's research findings at the BIO-Europe 2026 conference.
The details
Andrew Yates will deliver the presentation on behalf of Artelo Biosciences, which is based in Solana Beach, California. The selection for the showcase was determined by a committee of venture investors and industry professionals.
Timeline
November 9-11, 2026: BIO-Europe 2026 conference dates.
November 10, 2026: Artelo company presentation at 4:15pm CET.
The Tech Race
The conference utilizes the BIO-Europe partnering portal to facilitate thousands of one-to-one meetings between investors and drug developers. Artelo Biosciences' participation represents a growing effort among biotech firms to secure early-stage research collaborations.
The presentation offers potential insight into future treatment options for patients suffering from chronic pain and inflammation. If the drug advances through clinical trials, it could eventually offer a safer alternative to current non-steroidal anti-inflammatory drugs.
The takeaway
The selection of Artelo Biosciences by an industry panel highlights the rising interest in inhibitors of fatty acid binding protein 5. Future updates regarding the company's clinical progress will remain a key focus for investors following the industry event.
Further reading
For more information on industry trends, see the Biotech section.
Live Poll
Do clinical trial updates from pharmaceutical companies increase your trust in future medical treatment options?
